婴儿心脏手术中甲基泼尼松龙的应用:一项随机对照试验的亚组分析
该研究为STRESS试验的亚组分析,纳入24个先天性心脏病中心的1200例接受体外循环心脏手术的婴儿(<1岁),随机接受甲基泼尼松龙30 mg/kg或安慰剂加入体外循环预充液。结果显示,甲基泼尼松龙与新生儿、STAT 1-3和4-5组、足月儿及无染色体或综合征诊断者术后氢化可的松使用减少相关,并与新生儿和足月儿血栓形成减少相关;但早产儿血栓形成增加(p=0.005),新生儿和STAT 1-3组急性肾损伤增加,所有亚组血糖峰值和胰岛素暴露均增加(p<0.001),总体感染无增加,机械通气延长无减少。作者认为减少术后氢化可的松使用和不增加感染支持预防性使用,但血糖升高和急性肾损伤的中性至有害关联提示需权衡。
要点
- 婴儿心脏手术预防性甲基泼尼松龙30 mg/kg加入体外循环预充液可减少新生儿术后氢化可的松使用(OR 0.39,95%CI 0.25-0.60)。
- 甲基泼尼松龙与新生儿血栓形成减少相关(OR 0.37,95%CI 0.16-0.87),但早产儿血栓形成增加(p=0.005)。
- 甲基泼尼松龙与新生儿急性肾损伤增加相关(OR 1.55,95%CI 1.02-2.37),STAT 1-3组急性肾损伤也增加(OR 1.34,95%CI 1.02-1.75)。
- 所有亚组中甲基泼尼松龙均与血糖峰值和胰岛素暴露增加相关(p<0.001),总体感染率无增加,机械通气延长无减少。
适用人群与场景
- 接受体外循环心脏手术的婴儿(<1岁),按STAT死亡类别、年龄、胎龄及染色体或综合征诊断进行亚组分析。
- 研究在24个先天性心脏病中心进行。
处置流程与药物剂量
- 甲基泼尼松龙30 mg/kg加入体外循环预充液,与安慰剂比较。
研究设计与关键结果
- 研究类型:双盲随机安慰剂对照试验(STRESS试验)的亚组分析,共1200例婴儿接受甲基泼尼松龙或安慰剂。
- 甲基泼尼松龙与新生儿术后氢化可的松使用减少相关(OR 0.39,95%CI 0.25-0.60),STAT 1-3组(OR 0.64,95%CI 0.46-0.89)、STAT 4-5组(OR 0.57,95%CI 0.34-0.97)、足月儿(OR 0.63,95%CI 0.47-0.83)及无染色体或综合征诊断者(OR 0.63,95%CI 0.46-0.86)也显示减少。
- 甲基泼尼松龙与新生儿血栓形成减少相关(OR 0.37,95%CI 0.16-0.87),足月儿血栓形成减少(OR 0.38,95%CI 0.19-0.75)。
- 甲基泼尼松龙与早产儿血栓形成增加相关(p=0.005)。
- 甲基泼尼松龙与新生儿急性肾损伤增加相关(OR 1.55,95%CI 1.02-2.37),STAT 1-3组急性肾损伤增加(OR 1.34,95%CI 1.02-1.75)。
- 所有亚组中甲基泼尼松龙均与血糖峰值和胰岛素暴露增加相关(p<0.001)。
- 总体感染率无增加,机械通气延长无减少。
证据类型、等级与局限
- 证据类型:随机对照试验的亚组分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,减少术后氢化可的松使用和不增加感染率支持预防性使用甲基泼尼松龙。
- 作者指出,甲基泼尼松龙与血糖峰值升高及急性肾损伤的中性至有害关联需权衡,某些亚组可能受益且无显著危害。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Evaluate benefits and harms of prophylactic intraoperative methylprednisolone in subpopulations undergoing infant heart surgery.
DESIGN: Subpopulation analyses of The Steroids to Reduce Systemic Inflammation after Infant Heart Surgery (STRESS) trial, a double-blind randomized placebo-controlled trial.
SETTING: Twenty-four congenital heart centers.
PATIENTS: Infants (< 1 yr old) undergoing heart surgery with cardiopulmonary bypass. Patients stratified by Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery Congenital Heart Surgery (STAT) mortality category, age, gestational age, and presence of chromosomal or syndromic diagnosis (CSD).
INTERVENTIONS: Methylprednisolone (30 mg/kg) vs. placebo administered into cardiopulmonary bypass pump-priming fluid.
MEASUREMENTS AND MAIN RESULTS: Six postoperative outcomes: steroid use, acute kidney injury (AKI), thrombosis, infections, prolonged mechanical ventilation, peak blood glucose levels, and insulin exposure. One thousand two hundred patients received methylprednisolone or placebo. Beneficial effects associated with methylprednisolone included reduced use of postoperative hydrocortisone in neonates (odds ratio [OR], 0.39 [0.25-0.60]), both STAT category groups (1-3: OR, 0.64 [0.46-0.89]; 4-5: OR, 0.57 [0.34-0.97]), term infants (OR, 0.63 [0.47-0.83]), and those without CSD (OR, 0.63 [0.46-0.86]). Methylprednisolone was associated with lower thrombosis occurrence among neonates (OR, 0.37 [0.16-0.87]) and term infants (OR, 0.38 [0.19-0.75]). Adverse associations included increased thrombosis among premature infants ( p = 0.005), increased AKI among neonates (OR, 1.55 [1.02-2.37]) and those following STAT category 1-3 operations (OR, 1.34 [1.02-1.75]), and increased peak blood glucose levels and insulin exposure (all subgroups; p < 0.001). No increase in overall infection or reduction in prolonged mechanical ventilation with methylprednisolone.
CONCLUSIONS: Both beneficial and adverse associations were observed with prophylactic methylprednisolone. Reduction in postoperative hydrocortisone administration and absence of increased infection rates are arguments favoring prophylactic methylprednisolone use. Methylprednisolone was associated with increased peak blood glucose levels and a neutral to harmful association with odds of AKI. These data suggest certain subpopulations may benefit from prophylactic intraoperative methylprednisolone without significant harm.
参考来源
- Sunthankar SD, Hill KD, Jacobs JP, et al. Methylprednisolone for Infant Heart Surgery: Subpopulation Analyses of a Randomized Controlled Trial. Crit Care Med. 2025. PMID: 40396812. doi:10.1097/CCM.0000000000006721
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。